NHF and HFA are members of the American Plasma Users Coalition.
The FDA approval is for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors.
What you need to know about access to HTCs
Supplemental MASAC Statement Regarding Home Delivery and Refill Under State of Emergency Declaration
Having an adequate supply of treatment products at home is critical to achieve safe patient care and continuity of treatment.
On March 27th, experts from NHF answered your questions regarding changes in insurance in our townhall webinar: Insurance: Coping During COVID-19.
MASAC's latest set of recommendations cover the use and management of emicizumab, the latest products licensed to treat bleeding disorders, integrating the CDC's opioid prescribing guidelines into bleeding disorders care, and bleeding prophylaxis for patients undergoing gastrointestinal endoscopies.
On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community.
Information and techniques you and your family can use to stay healthy during the COVID-19 pandemic.
Do you have questions regarding insurance coverage in light of the COVID-19 pandemic? We're here to help.
The halted trials were investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status.